



IDWeek²⁰¹⁶TM

Advancing Science, Improving Care

ADDENDUM TO THE *FINAL PROGRAM AND ABSTRACTS* (as of 10/21/16)

Copyright, Disclaimer, and Related Policies

All materials included on the IDWeek website and/or audio media are subject to copyrights owned by IDSA, SHEA, HIVMA, and PIDS or other individuals or entities. Any reproduction, retransmission or republication of all or part of any document is strictly prohibited, unless the copyright owner of the material has expressly granted its prior written consent to so reproduce, retransmit or republish the material. All other rights reserved.

Abstracts

Abstracts are available electronically on the IDWeek Interactive Program Planner. Visit www.idweek.org and under program, click on the "Interactive Program" to view the complete abstracts. Create your itinerary using the Interactive Program Tool and download abstracts to PDF. Abstracts will also be available via OFID on October 26, 2016.

IDWeek Meeting Surveys and Claiming CME/CPE/MOC Credit

IDWeek meeting surveys can be completed online after the meeting – watch your email for a link.

Individual session evaluations are completed online through the process of claiming CME/CPE/MOC credit. **The deadline to claim credit is December 2, 2016.** Visit www.idweek.org/post-meeting-tools for details about how to claim credit and complete session evaluations.

IDWeek Special Events

Don't miss out on these special IDWeek events!

SHEA Business Meeting
Thursday, October 27, 5:45 – 6:30 p.m., 275-277

Career Networking Event
Thursday, October 27, 6 – 8 p.m., 271-273
Top employers from across the nation will come together with qualified infectious diseases specialists seeking employment. Participating companies represent a variety of practice types, with positions ranging from novice to experienced clinicians, all looking to hire infectious diseases specialists.

PIDS Business Meeting
Friday, October 28, 5:45 – 6:30 p.m., 283-285

IDWeek 2016 Town Hall: Securing the Future of ID
Friday, October 28, 6 – 7:30 p.m., Theater A&B
Join a lively discussion with colleagues, learn about what IDSA and HIVMA are doing to promote the field of infectious diseases to medical students, residents, payers and policymakers, and contribute your opinions and ideas about the future of ID.

IDBugBowl
Saturday, October 29, 10:30 a.m. – noon., Theater C
Come match your knowledge of ID Trivia with contestants from three New Orleans ID programs! The teams will battle it out to see who comes out on top in the inaugural IDBugBowl.

Program and Abstract Updates

Session 3. Symposium
Current Controversies in Infection Prevention
Wednesday, October 26, 1:30-3:30 p.m.
Presentation. Use of Process Measures for Quality Improves Patient Outcomes – Pro will now be given by Neil Fishman, MD, FIDSA, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Session 9. Meet the Professor
Brain Teasers: Challenging Cases in Neurologic Infection
Thursday, October 27, 7 – 8:15 a.m.
Will be presented by Karen Bloch, MD, MPH, FIDSA, Vanderbilt University Medical Center, Nashville, TN

Session 24. Symposium
How Good Is the Pediatric Guidance? Highlights, Controversies, and Implementation
Thursday, October 27, 8:30 – 10 a.m.
Presentation 53: Management of Infectious Diarrhea in Children and Adults
Will be presented by Andi L. Shane, MD, MPH, MSc, FIDSA, FPIDS, Emory University School of Medicine, Atlanta, GA

Session 34. Interactive Session
Approach to "High-Hanging" Fruit in ASP Implementation
Thursday, October 27, 10:30 a.m. – noon
New panelist: Anurag Malani, MD, FIDSA, St. Joseph Mercy Health System, Ypsilanti, MI

Session 42. Oral Abstract Session

Thursday, October 27, 10:30 a.m. – noon

Presentation 119. Previous Daptomycin Exposure Predicts Daptomycin Non-Susceptible Enterococcus faecium Bloodstream Infections in Adult Leukemia Patients will now be presented by Adam J. Dipippo, PharmD

Session 55. Poster Abstract Session

HAI: Multi Drug Resistant Gram Negatives

Thursday, October 27, 12:30 – 2 p.m.

Presentation 335: Carbapenemase-Producing Gram-Negative Bacteria in England: Results from The First Year of Enhanced Surveillance has been withdrawn.

Session 57. Poster Abstract Session

HAI: Preventing Device-Associated Infections

Thursday, October 27, 12:30 – 2 p.m.

Presentation 398: Does Catheter Removal in Time Save Nine? Optimizing Post-Operative Urinary Catheter Removal to Prevent Post-Operative Catheter-Associated Urinary Tract Infection (CAUTI) in US Adult (18+ year-old) Surgical Inpatients, has been withdrawn.

Session 67. Poster Abstract Session

Tuberculosis Epidemiology and Diagnosis

Thursday, October 27, 12:30 – 2 p.m.

Presentation 552: Delay in the Diagnosis of Tuberculosis and Initiation of TB Treatment in the Private Health Sectors versus Public Health Sectors in Rajasthan, India 2013 Has been withdrawn.

Session 72. Poster Abstract Session

They've Been Here a Billion Years! Pediatric Bacterial and Viral Infections

Thursday, October 27, 12:30 – 2 p.m.

Presentation 697: Non-type B Haemophilus influenzae Invasive Infections in North Dakota and South Dakota, 2013-15 has been withdrawn.

Session 74. Poster Abstract Session

74. Vaccines: Adolescent HPV and Meningococcal

Thursday, October 27, 12:30 – 2 p.m.

Presentation 723 is now 723a: A Booster Response to an Investigational Meningococcal MenABCWY Vaccine in Adolescents Previously Vaccinated with MenACWY, 4CMenB or MenABCWY: a Phase 2, Observer-Blind, Placebo-Controlled, Randomized Study

Presentation 723b has been added: Investigational Meningococcal ABCWY Vaccine is Effective against a Broad Panel of Serogroup B Invasive Disease Strains in US Adolescents: a Phase 2, Controlled, Randomized Study

Session 84. Poster Discussion Round

Vaccines

Thursday, October 27, 12:30-2 p.m.

Group Leader is now Robert W. Frenck Jr., MD, FIDSA, University of Cincinnati, Cincinnati, OH

Session 89. Symposium

MERS: Four Years On

Thursday, October 27, 2 – 3:30 p.m.

Presentation 824. Clinical Features of MERS-CoV in Saudi Arabia is now titled MERS-CoV in an Emergency Room: Epidemiology of Outbreak and Control Measures and will be presented by Yae-Jean Kim, MD, PhD, Samsung Medical Center, Seoul, South Korea

Session 93. Symposium

Treating Infectious Disease in a Resource-Limited Setting

Thursday, October 27, 2 – 3:30 p.m.

Presentation 836. Challenges with Using Laboratory Testing to Manage Patient Care will now be given by Corey Forde, MD, DM, Queen Elizabeth Hospital, Christ Church, Barbados

Session 103. Meet the Professor

How to Make ID Learning Active

Friday, October 28, 7 -8:15 a.m.

Will be presented by Wendy Stead, MD, Harvard Medical School, Boston, MA

Session 130. Symposium

What Comes First: Innate Immunity. What the ID Physician Needs to Know

Friday, October 28, 10:30 a.m. – noon

Presentation 939. Pathogen Recognition Receptors and Their Role in Defining the Immune Response will now be given by Mairi Noverr, PhD, Louisiana State University School of Medicine, New Orleans, LA

Session 149. Poster Abstract Session

Public Health

Friday, October 28, 12:30 – 2 p.m.

Presentation 1431: Geographical Information Software and Shopper Card Data, Aided in the Discovery of a Salmonella Enteritidis Outbreak Associated with Turkish Pine Nuts Has been withdrawn.

Session 163. Poster Abstract Session

Mycology - There's a Fungus Among Us: Treatment

Friday, October 28, 12:30 – 2 p.m.

Presentation 1626: abcdef has been withdrawn.

Session 173. Symposium

Mists, Rays, and Robots – Environmental Cleaning in the 21st Century

Friday, October 28, 2-3:30 p.m.

Presentation 1661. Review of Environmental Infection Prevention Strategies – What is the Current State of the Evidence? will now be at 2:30 p.m.

Session 174. Symposium

Next-Generation Sequencing: Transforming Public Health

Friday, October 28, 2-3:30 p.m.

Presentation 1666. Mobilizing Nanopore Sequencing to Stop an Ebola Outbreak: Lessons from Guinea will now be given by Lauren Cowley, PhD, Harvard School of Public Health, Boston, MA

Session 179. Oral Abstract Session

Vaccines in the Young and Vulnerable

Friday, October 28, 2 – 3:30 p.m.

Presentation 1685. A Randomized, Consistency Study Comparing Immunogenicity and Safety of 2 Vaccines Against Measles, Mumps and Rubella (MMR) Administered to Children 12–15 Months of Age will be presented by **Nicola P. Klein, MD, PhD**

Presentation 1689. Safety of Live Attenuated Influenza Vaccine Versus Inactivated Influenza Vaccine in Asthmatic Children will be presented by **Nicola P. Klein, MD, PhD**

Session 200. Symposium

Infectious Diseases in the Americas: Bugs without Borders

Saturday, October 29, 8:30-10:00 a.m.

Session will now end at 10:15 a.m.

Session 202. Symposium

Pediatric Infection Prevention: Keeping Healthy Children In and Pathogens Out

Saturday, October 29, 8:30 -10:00 a.m.

Presentation 1733's title is now: Infection Prevention in the NICU: Small but mighty!

Session 247. Poster Abstract Session

New Antibiotics in Development

Saturday, October 29, 12:30 – 2 p.m.

Presentation 2253: Investigational Meningococcal ABCWY Vaccine is Effective against a Broad Panel of Serogroup B Invasive Disease Strains in US Adolescents: a Phase 2, Controlled, Randomized Study
Is now 723b and will be presented in Poster Abstract Session: 74. Vaccines: Adolescent HPV and Meningococcal

Session 267. Oral Abstract Session

Epidemiology and Outcomes of Resistant Gram-Negative Organisms

Saturday, October 29, 2 – 3:30 p.m.

Presentation 2373: Identification of a colistin- and carbapenem-resistant Escherichia coli strain harboring both mcr-1 and NDM at a large tertiary-care urban hospital in Newark, New Jersey.

Has been withdrawn and replaced with **Presentation 2373:** Healthcare Antibiotic Resistance Prevalence – DC (HARP - DC)- Measuring the Prevalence of Carbapenem Resistant Enterobacteriaceae in Healthcare Facilities (HCF) in Washington DC

Additional Financial Disclosures

Author (Session)

Company: Relationship

Mark Awad (86)

Nothing to disclose

Nesli Basgoz (260)

Allergan, Role: Board Member, Received: Board fees, equity

Deborah L. Birx (8)

Nothing to disclose

Philip J. Budge (PW1)

Nothing to disclose

Michael V. Callahan (190)

Nothing to disclose

Henry Chambers (191, 260)

Allergan, Role: Scientific Advisor, Received: Consulting fee; Medicines Company, Role: Grant investigator, Received: Research grant; Genentech, Role: Grant Investigator and Scientific Advisor, Received: Research grant and Consulting fee

Peter Chin-Hong (124)

Nothing to disclose

Christopher Crnich (173)

Nothing to disclose

Benjamin Davis (PW4)

Did not disclose

John P. DeVincenzo (175)

Pulmocide Pharmaceutical, Role: Collaborator, Research Contractor, Scientific Advisor, Received: Research support; Ark Pharmaceutical, Role: Collaborator, Research Contractor, Scientific Advisor, Received: Research support

Curtis Donskey (208)

Nothing to disclose

Erik R. Dubberke (PW2, 182)

Rebiotix, Role: Investigator and Scientific Advisor, Received: Research Support, Consulting fee; Merck, Role: Consultant, Investigator, Received: Research support, Consulting fee; Sanofi Pasteur, Role: Consultant, Grant Investigator, Received: Grant recipient, Consulting fee; Summit, Role: Consultant, Received: Consulting fee

Mark Feinberg (126)

Merck, Role: Consultant, Shareholder (excluding diversified mutual funds), Received: Consulting fee

Neil F. Fishman (3)

Nothing to disclose

Victoria Fraser (187)

Express Scripts, Role: Other (Spouse is Senior Vice President and Chief Medical Officer), Received: Other (Spouse employment)

Scott Halstead (201)

Nothing to disclose

James P. Harnisch (110)

Nothing to disclose

Jeffrey P. Hendersron (263)

Nothing to disclose

Dimitrios P. Kontoyiannis (260)

Merck, Role: Scientific Advisor, Speakers Bureau, Received: Speaker honorarium, Consulting fee; Astellas, Role: Consultant, Received: Consulting fee; Cidara, Role: Consultant, Received: Consulting fee; Amplyx, Role: Consultant, Received: Consulting fee; F2G, Role: Consultant, Received: Consulting fee

Grace McComsey (38)

Gilead, Role: Consultant, Grant Investigator, Scientific Advisor, Received: Research grant, Consulting fee; BMS, Role: Consultant, Grant Investigator, Received: Research grant, Consulting fee; ViiV/GSK, Role: Consultant, Grant Investigator, Received: Research grant, Consulting fee

Douglas Osmon (85)

Nothing to disclose

Anjum Owaisi (111)

Nothing to disclose

Susan Prockop (86)

Atara Biotherapeutics, Role: Other (Atara Biotherapeutics holds the IND and has a license to develop and commercialize the cell therapy program I will be discussing today. I have no personal conflicts but MSKCC and several MSK investigators currently hold a financial interest in Atara Biotheapeutics), Received: I have received no financial or in kind benefit.

Laura Riley (21)

Nothing to disclose

Nasia Safdar (41)

Nothing to disclose

Paul Sax (112)

AbbVie, Role: Scientific Advisor, Received: Consulting fee; BMS, Role: Grant Investigator, Scientific Advisor, Received:

Research grant, Consulting fee; GlaxoSmithKline/ViiV, Role: Grant Investigator, Scientific Advisor, Received: Research grant, Consulting fee; Gilead, Role: Grant Investigator, Scientific Advisor, Received: Research grant, Consulting fee; Janssen, Scientific Advisor, Received: Consulting fee; Merck, Scientific Advisor, Received: Consulting fee

Seren Spudich (185)

Nothing to disclose

Ann E. Stapleton (209)

Nothing to disclose

Edward Stenehjem (PW2, 266)

Pfizer, Role: Grant Investigator, Received: Research grant; Allergan, Role: Grant Investigator, Received: Grant recipient

Kurt Stevenson (208)

Nothing to disclose

Gregory Storch (36)

Did not disclose

Babafemi Taiwo (38, 112)

ViiV, Role: Consultant, Investigator, Received: Research grant, Consulting fee; Gilead, Role: Consultant, Received: Consulting Fee

Kavita Trivedi (34, 128)

Nothing to disclose

Kamini Walia (93)

Nothing to disclose

Yana Zavros (17)

Nothing to disclose

IDWeek Poster Discussion Rounds

IDWeek Poster Discussion Rounds will take place from 12:30 – 2 p.m. in the following areas:

IDExpo Hall – Area A

Thursday, October 27

80. Diagnostics

Friday, October 28

164. Antibiotics Stewardship: General Acute Care Implementation (Adult)

Saturday, October 29

255. Antibiotic Stewardship: Pediatrics

Plus

IDExpo Hall – Area B

Thursday, October 27

81. Environment/Cleaning

Friday, October 28

165. Clinical Advances

Saturday, October 29

256. *Clostridium difficile*

IDExpo Hall – Area D

Thursday, October 27

83. Pediatric Bacterial and Viral

Friday, October 28

168. Surgical Site Infections

Saturday, October 29

258. Resistance

IDExpo Hall – Area C

Thursday, October 27

82. Global Health

Friday, October 28

166. HIV

Saturday, October 29

257. New Antibiotics


IDExpo Hall – Area E

Thursday, October 27

84. Vaccines

Saturday, October 29

259. Transplants and Immunocompromised Host





The Infectious Diseases Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Credit Designation Statement

IDSa designates this live activity for a maximum of 42 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity. **The deadline for completing the evaluations is Friday, December 2, 2016.**



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



The continuing education activities for pharmacists have been developed through a joint providership of ProCE, Inc. and the Infectious Diseases Society of America (IDSa). ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Numbers 0221-9999-16-200-L05-P through 0221-9999-16-307-L04-P have been assigned to these live knowledge-based and application-based sessions (initial release date October 25-30, 2016). This conference is acceptable for up to 40.25 contact hours (4.025 CEUs) in states that recognize ACPE providers. The registration fee covers the cost of CE credits. CE Statements will be issued by the Infectious Diseases Society of America (IDSa) at the conclusion of the conference. Participants must complete an evaluation for each session they attended to receive pharmacy CE credit. The deadline for completing the evaluations is **Friday, December 2, 2016.**